Vorolanib plus Sintilimab for advanced kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests two drugs together—vorolanib (a pill that targets blood vessels in tumors) and sintilimab (an immunotherapy that helps your immune system fight cancer)—for people with advanced kidney cancer whose prior immunotherapy combination stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have kidney cancer that has spread to other parts of your body (stage IV).
- You must have already tried an immunotherapy treatment and it stopped working.
- You must be willing to provide some of your tumor tissue and blood for testing.
- Your kidneys, liver, and blood counts must be within certain limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs (ipilimumab, sintilimab, and lenvatinib) as a first treatment for a rare and advanced type of kidney cancer called TFE3-rearranged renal cell carcinoma. The goal is to see if this combination can shrink tumors and help people live longer.
This trial tests a combination of two drugs, Vorolanib and Cadonilimab, for people with advanced or metastatic clear cell kidney cancer who have not had prior treatment. It aims to see if the combination shrinks the cancer and how safe it is.
This trial tests a combination of two drugs (tivozanib and nivolumab) for people with advanced kidney cancer that is not clear cell type. It aims to see if this drug pair can shrink or slow the cancer.
This trial tests a targeted therapy pill, vorolanib, for people with advanced kidney cancer that has clear cell features and has gotten worse after initial treatment. It may offer a new option when standard second-line treatments are not working.
This trial tests a new combination of two oral drugs (vorolanib plus everolimus) versus the standard drug sunitinib in people with advanced clear cell kidney cancer that got worse after immunotherapy alone or with a targeted therapy. The goal is to see if the new combination works better.
This trial tests a combination of two drugs — voronib and everolimus — for people with clear cell kidney cancer whose previous targeted therapy and immunotherapy have stopped working. The goal is to see if this new combination can help when other treatments have failed.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.